



LKT Laboratories, Inc.

(-)-Huperzine A

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID H8162

CAS No. 102518-79-6

Chemical Name 1-amino-13-ethylidene-11-methyl-6-aza-tricyclo- [7.3.1.0^{2,7}]trideca-2(7),3,10-trien-5-one

Synonym HupA


Formula C₁₅H₁₈N₂O

Formula Wt. 242.32

Melting Point 214-215°C

Purity ≥97%

Solubility Soluble in DMSO, ethanol, methanol, and aqueous acids.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
H8162	1 mg	\$139.00
H8162	5 mg	\$612.70

Store Temp 4°C

Ship Temp Ambient

Description Huperzine A (HupA) is a sesquiterpene alkaloid derived from the fir-like moss *Huperzia serrata*; it exhibits anticonvulsant/antiepileptic, neuromodulatory, cognition enhancing, neuroprotective, and antinociceptive activities. HupA acts as a reversible, selective acetylcholinesterase (AChE) inhibitor and is being explored in clinical trials as a potential treatment for Alzheimer's Disease. Several studies have shown HupA to improve cognition, memory, mood, and/or daily activities at a range of doses. Additionally, HupA's comparatively long-lasting binding of AChE is protective against organophosphate-induced seizure and status epilepticus. In cellular and animal models, this compound exhibits non-competitive, reversible antagonist activity at NMDA receptors. HupA is also under examination as a potential non-dependence-inducing antinociceptive, as it blocks chemical, thermal, and mechanical pain stimulation in vivo.

References Yu D, Thakor DK, Han I, et al. Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. *Proc Natl Acad Sci U S A*. 2013 Feb 19;110(8):E746-55. PMID: 23386718.

Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. *Neurology*. 2011 Apr 19;76(16):1389-94. doi: PMID: 21502597.

Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. *Neurosci Lett*. 2010 Feb 5;470(1):6-9. PMID: 20026382.

Zhang Z, Wang X, Chen Q, et al. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. *Zhonghua Yi Xue Za Zhi*. 2002 Jul 25;82(14):941-4. PMID: 12181083.

Gordon RK, Nigam SV, Weitz JA, et al. The NMDA receptor ion channel: a site for binding of Huperzine A. *J Appl Toxicol*. 2001 Dec;21 Suppl 1:S47-51. PMID: 11920920.

Camps P, El Achab R, Morral J, et al. **New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.** *J Med Chem*. 2000 Nov 30;43(24):4657-66. PMID: 11101357.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.